5:57 PM
 | 
Nov 28, 2012
 |  BC Extra  |  Clinical News

Researchers question benefits of K-Ras screening

Researchers at the HealthPartners Research Foundation said screening for K-Ras (KRAS) mutations prior to starting treatment with Erbitux cetuximab saves about $7,500 over 10 years in metastatic colorectal cancer (mCRC) patients compared with not screening. However, the researchers found the incremental cost effectiveness ratio (ICER) per life year saved (LYS) gained with screening is still above "the generally...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >